Luca Pani - European Medicines Agency

Curriculum Vitae
PERSONAL INFORMATION
Luca Pani
WORK EXPERIENCE
January 2013–Present
Member
EMA, (United Kingdom)
Member of the European Risk Management Strategy Facilitation Group (ERMS-FG)
November 2013–Present
Chair<p>Chair of the European Union Management Board Telematic Committee
(EUMBTC) </p
EMA, (United Kingdom)
Chair of the European Union Management Board Telematic Committee (EUMBTC)
November 2011–Present
Director General
Italian Medicines Agency (AIFA), (Italy)
Director General of the Italian Medicines Agency (AIFA)
January 2012–Present
Member
EMA, (United Kingdom)
Member of the Management Board Telematics Committee (MBTC) of the European Medicine Agency
(EMA)
January 2011–Present
Management Board EMA Member
EMA, (United Kingdom)
Management Board EMA Member
January 2011–Present
Voluntary Professor
University of Miami– M. Miller School of Medicine (Department of Psychiatry & Behavioral Sciences),
(United States)
Voluntary Professor of the University of Miami– M. Miller School of Medicine (Department of
Psychiatry & Behavioral Sciences)
January 2010–Present
Italian Permanent Member, Committee for Human Medicine Products (CHMP)
EMA, (United Kingdom)
Italian Permanent Member, Committee for Human Medicine Products (CHMP),
European Medicines Agency (EMA)
January 2010–Present
Member of theWorking Party on Central Nervous System (WP-CNS)
EMA, (United Kingdom)
Member of theWorking Party on Central Nervous System (WP-CNS), European
Medicines Agency (EMA
January 2010–Present
Member of the Scientific Advice Working Party (SA-WP)
EMA, (United Kingdom)
Member of the Scientific Advice Working Party (SA-WP), European Medicines Agency (EMA)
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 1 / 25
Curriculum Vitae
January 2009–December 2011
Luca Pani
Member Committee for Clinical Neurosciences
AIFA, (Italy)
Member, Committee for Clinical Neurosciences, Italian Medicines Agency (AIFA)
January 2009–December 2011
Head of the National Research Council’s Institute of Translationalpharmacology
CNR , (Italy)
Headof Research of the National Research Council’s Institute of Translationalpharmacology (CNR –
ITP), located in Pula-Cagliari
January 2008–December 2010
Consultant
Media Ltd Consultant, (United Kingdom)
3PS Media Ltd Consultant
January 2008–December 2011
Founder and Permanent Member of the Scientific Board of Fase 1
Regione Autonoma della Sardegna, (Italy)
Founder and Permanent Member of the Scientific Board of Fase 1, the first Government based
(Regione Autonoma della Sardegna) Contract Research Organization dedicated to Fase 1 studies in
Translational Pharmacology
January 2006–December 2010
Head Section of Neuropharmacology Pula-Cagliari
Milano Italian National Research Council , (Italy)
Head Section of Neuropharmacology Pula-Cagliari, Institute of Biomedical Technologies, Milano
Italian National Research Council
January 2002–Present
Director of Research
Italian National Research Council, (Italy)
Director of Research, Italian National Research Council. Cagliari
January 2002–December 2010
President
Pharmaness Neuroscienze, (Italy)
President, Pharmaness Neuroscienze(Board of Directors member – Resignation: August 5th, 2010)
January 2004–December 2009
President
Proteios Srl , (Italy)
President, Proteios Srl (closed)
January 2005–December 2008
President
ProKemia Consorzio Regione Autonoma Sardegna, (United Kingdom)
President ProKemia Consorzio (closed)
January 2001–December 2001
Senior Researcher
Institute of Neurogenetic and Neuropharmacology. National Research Council,, (Italy)
Senior Researcher Institute of Neurogenetic and Neuropharmacology. National Research Council,
Cagliari
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 2 / 25
Curriculum Vitae
January 1999–December 2002
Luca Pani
CEO
Pharmaness Neuroscienze, (Italy)
CEO, Pharmaness Neuroscienze
January 1992–December 1993
Research Assistant Professor
Fidia Georgetown Institute for the Neurosciences and Department of Pharmacology, Georgetown
University School of Medicine, (United States)
Research Assistant Professor Fidia Georgetown Institute for the Neurosciences and Department of
Pharmacology, Georgetown University School of Medicine. Washington, D.C.
January 1990–December 1992
Research Associate
University of Illinois , (United States)
Research Associate. Dept. of Biochemistry University of Illinois at Chicago
January 1988–December 1989
Medical Assistant
Psychiatric Hospital “Villa Clara”, (Italy)
Medical Assistant (tenured). Psychiatric Hospital “Villa Clara”. Cagliari
January 1985–December 1988
Resident in Psychiatry
Centro Lucio Bini, (Italy)
Resident in Psychiatry, Centro Lucio Bini, Prof. Athanasio Koukopoulos Mentor and Clincal
Supervisor, Rome
EDUCATION AND TRAINING
September 1992–June 1994
Assistant Professor
Georgetown University, (United States)
Assistant Professor in Molecular Biology and Pharmacology
January 1990–December 1991
Post Doctoral
University of Illinois, (United States)
Post Doctoral Fellowship in Molecular Biology
January 1985–December 1989
Specialty in Psychiatry
University of Naples, (Italy)
Specialty in Psychiatry
January 1986–December 1988
Medical Officer
Italian Navy Head of South Sardinia Command General Medicine Headquarters, (Italy)
September 1979–June 1985
Medical Degree
University of Cagliari, (Italy)
ADDITIONAL INFORMATION
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 3 / 25
Curriculum Vitae
Expertise
Luca Pani
Luca Pani from 2002 to 2010 has been the President of PharmaNess Scarl (PharmaNess) one of the
most important European non-profit Research Centres focusing on pharmacology and biotechnology
(see www.pharmaness.it). PharmaNess’ shareholders are currently fully private (100%), while until
2010 when he was President the University of Cagliari (16.4% www.unica.it) and the National
Research Council of Italy (8.6% circa www.cnr.it), held part of the shares. PharmaNess held a leader
position in the Biomedicine District of Sardinia and it worked in close collaboration with prestigious
Universities, research institutes and private organizations located in Italy and in other countries.
2007 -2010 Luca Pani entered a partnership with John Fairbairn and Bruno Kavanaugh (www.casebuilder.com) for the highest level of medical education and information dissemination in the field of
Mental Disorders.
1990-1991 Fidia Research Foundation International Fellowship in Neuroscience.
Platano d’Oro: Italian National Medical Writing Prize, Finalist in all the first three editions of the prize
(1994-1996-1998).
Luca Pani contributes regularly to the Science Almanac of the Italian Research Council
(www.almanacco.rm.cnr.it) the largest Italian Research Institution.
Luca Pani is (or has been) a member of the Italian Society of Pharmacology; Italian Society of
Psychopathology; Italian Society of Psychiatry; Italian Society for Psychoneuropharmacology.
National Expert with the task force on Bionanotechnology of the National Committee on Biosecurity
and Biotechnology for the Prime Minister Counsel (Presidenza del Consiglio dei Ministri) (see
www.governo.it/biotecnologie/documenti/Bionanotecnologie.pdf)
On Jan, 20th 2009 Luca Pani was appointed as Scientific Advisor in the Psychotic Disorders and
Antipsychotic Panel of the European College of Neuropsychopharmacology (ECNP). ECNP was
founded in 1987, is currently the largest platform of European Neuropsychopharmacologists and has
now more than 900 members.
Luca Pani has founded, launched and co-directed (1993-2003) with PP Pani and GL Gessa, The
Italian Journal of the Addictions (www.medicinatossicodipendenze.it) and has selected, judged and
edited the articles of the Journal over a decade.
Luca Pani is on the Editorial Board of Clinical Neuropsychiatry (www.clinicalneuropsychiatry.org); the
Italian Journal of Psychiatry and Psychotherapy, and the Italian Edition of the American Journal of
Psychiatry (www.arsxxi.it/AJP)
Committee Member for the career advancement of the highest position of Director of Research of the
National Research Council of Italy (www.cnr.it), the largest and most important research institution in
the Country.
For the period 2007-2010 Luca Pani has been appointed by the Italian Research Council as Deputy
Representative in the International Committee on Laboratory Animal Science (ICLAS)
Since 2007 Luca Pani has been appointed in the Scientific Board of Directors of Fase Uno
www.sardegnaricerche.it/fase1/ the first Government based Contract Research Organization
dedicated to early stage Clinical Trials in Drug Discovery. In 2011 he resigned.
Since 2009, Member on the Technical Committee for Clinical Neurosciences at the AIFA (The Italian
equivalent of the Federal Drug Agency).
2009-2014 Member on the Technical Committee for Pharmaceutical Support of the Regione
Autonoma della Sardegna.
Publications
1) Serra G; Collu M; D'Aquila P; Pani L; Gessa G
Are D1 DA receptors agonist potential antidepressant?
Pharmacol. Res. Comm. 1988 20 12 1121 1123
2) Rossetti ZL; Pani L; Gessa GL.
Differential postmortem release of noradrenaline and dopamine from rat brain.
Psychopharmacology (Berlin) 1989; 98 (4): 562 563
3) Rossetti ZL; Pani L; Portas C; Gessa GL.
Brain dialysis provides evidence for D2 dopamine receptors modulating
noradrenaline release in the rat frontal cortex.
Eur J Pharmacol 1989 Apr 25; 163(2 3): 393 395
4) Rossetti ZL; Portas C; Pani L; Carboni S; Gessa GL.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 4 / 25
Curriculum Vitae
Luca Pani
Stress increases noradrenaline release in the rat frontal
cortex: prevention by diazepam.
Eur J Pharmacol 1990 Feb 6;176(2):229 31
5) Pani L; Carboni S; Kusmin A; Gessa GL; Rossetti ZL.
Nimodipine inhibits cocaine induced dopamine release and motor stimulation.
Eur J Pharmacol 1990 Feb 6;176(2):245 246
6) Pani L; Gessa GL; Carboni S; Portas CM; Rossetti ZL.
Brain dialysis and dopamine: does the extracellular concentration
of dopamine reflect synaptic release?
Eur J Pharmacol 1990 May 3;180(1):85 90
7) Carboni S; Melis F; Pani L; Hadjiconstantinou M; Rossetti ZL .
The non competitive NMDA receptor antagonist MK 801 prevents the massive release
of glutamate and aspartate from rat striatum induced by l methyl 4 phenylpyridinium (MPP+).
Neurosci Lett 1990 Sep 4;117(1 2):129 133
8) Rossetti ZL; Pani L; Kuzmin A; Carboni S; Gessa GL.
Dihydropyridine calcium antagonists prevent cocaine , but not amphetamine ,
induced dopamine release and motor activity in rats.
Acta Physiol Hung 1990;75 Suppl:249 250
9) Pani L; Kuzmin A; Stefanini E; Gessa GL; Rossetti ZL.
Flunarizine potentiates cocaine induced dopamine release and motor stimulation in rats.
Eur J Pharmacol 1990 Nov 6;190(1 2):223 227
10) Pani L; Kuzmin A; Diana M; De Montis G ; Gessa GL ; Rossetti ZL.
Calcium receptor antagonists modify cocaine effects in the central nervous system differently.
Eur J Pharmacol 1990 Nov 6;190(1 2):217 221
11) Pani L; Kuzmin A; Martellotta MC; Gessa GL; Fratta W.
The calcium antagonist PN 200 110 inhibits the reinforcing properties of cocaine.
Brain Res Bull 1991 Mar;26(3):445 447
12) Devoto P; Pani L; Kuzmin A; De Montis G.
Inhibition of 3H dopamine uptake by Flunarizine
Eur. J. Pharmacol. 1991 203 , 67 70
13) Diana M; Pani L; Rossetti Z; Passino N; Gessa G.L.
Flunarizine attenuates cocaine induced inhibition of A9 dopaminergic neurons.
Pharmacol. Res. 1991, 24, 197 203
14) Pani L., Kuzmin A., Diana M., De Montis G., Gessa G.L., Rossetti Z.
Dihydropyridine calcium antagonists prevent cocaine-induced dopamine release
and motor activity in rats
Posters in Neuroscience, 1991, 1, 85-88
15) Pani L; Clevidence D; Qian X ; Costa R.H.
The restricted promoter activity of the liver transcription factor Hepatocyte Nuclear
Factor 3 involves a cell specific factor and positive autoactivation.
Molecular and Cell Biology1992 , XII, 552 562
16) Pani L; Overdier D.G; Porcella A; Qian X; Lai E; Costa R.H.
Hepatocyte Nuclear Factor 3ß contains two transcriptional activation domains, one of which is novel
and conserved with the Drosophila Fork Head protein.
Molecular and Cell Biology 1992 , XII, 3723-3732.
17) Clevidence D.E; Overdier D.G; Tao W; Qian X; Pani L; Lai E; Costa R.H.
Identification of Nine Novel Tissue-Specific Transcription factors of the Hepatocyte nuclear factor 3 /
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 5 / 25
Curriculum Vitae
Luca Pani
Forkhead DNA-Binding-Domain Family.
P.N.A.S. 1993, 90, 3948-3952.
18) Cavallaro S.; Pani L.; Guidotti A.; Costa E.
ACTH induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in
adrenal of hypophysectomized rat in not cause-effect relatedto its immediate steroidogenic action.
Life Sciences 1993, 53:1137-1147.
19) Kolmer M; Alho H; Costa E; Pani L.
Cloning and tissue specific functional characterization of the rat Diazepam Binding Inhibitor promoter.
P.N.A.S. 1993, Vol. 90, 8439-8443.
20) D’Aquila PS; Collu M; Pani L; Gessa GL ; Serra G.
Antidepressant-like effect of selective D1 receptors agonist in the behavioural despair animal model of
depression.
Eur. J. Pharmacol. 1994, 262, 107-111
21) Fadda P., Pani L., Porcella A., Fratta W.
Chronic imipramine, L-Sulpiride and mianserin decrease corticotropin releasing factor levels in the rat
brain.
Neurosci. Letters 1995, 192, 121-123
22) Gessa GL, Pani L., Fadda P., Fratta W.
Sleep deprivation in the rat: an animal model of mania.
Eur. Neuropsychopharmacology Suppl., 1995, 89-93
23) Samadani U., Porcella A., Pani L., Johnson P.F. Burch J., Pine R., Costa R.H.
Cytokine Regulation of the Liver Transcription Factor HNF-3ß is mediated by the C/EBP
Family and Interferon Regulatory Factor 1.
Cell Growth & Differentiation, 1995, 6, 879-890
24) Koukopoulos A., Pani L., Serra G., Minnai G., Reginaldi D.
La dépression anxieuse-excitée: un syndrome affectif mixte
L’Encéphale, 1995 ; VI Sp, 33-36
25) Colangelo A.M.; Pani L., Mocchetti I.
Correlation between increased AP-1 NGF binding activity and induction of nerve growth factor
transcription expression by multiple signal transduction in C6-2B glioma cells
Molecular Brain Research, 1996, 35, 1-10
26) Akiskal HS. Bolis CL. Cazzullo C. Costa e Silva JA. Gentil V. Lecrubier Y. Licinio J. Linden M.
Lopez-Ibor JJ. Ndiaye IP. Pani L. Prilipko L. Robertson MM. Robinson RG. Starkstein SE. Thomas P.
Wang Y. Wong ML., Dysthymia in neurological disorders.
Molecular Psychiatry., 1996, 1:478-491
27) Galli R. Michelini S. Bartalena L. Massetani R. Pani L. Grasso L. Cassano GB. Martino E. Purdy
RH. Murri L.,
Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the
intercritical phase.
Italian Journal of Neurological Sciences, 1996, 17:277-281,
28) Collu M. Poggiu AS. Pani L. Serra G.,
Fluoxetine-induced conditioned place preference: a preliminary study,
Synapse., 1997, 25:309-311.
29) Murru S. Pani L. Poddie D. Gessa G. Cao A. Pirastu M.
Rat tyrosine hydroxylase gene polymorphisms.
Molecular Brain Research., 1997, 45:345-348
30) Pani L. Gessa GL.
Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure.
International Journal of Clinical Pharmacology Research., 1997, 17:55-58.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 6 / 25
Curriculum Vitae
Luca Pani
31) Pani L. Gessa GL.
The role of dopamine in the biological basis of dysthymia.
Italian Journal of Psychiatry and Behavioural Sciences, 1998, 8:5-9
32) Porcella A. Gessa GL. Pani L.
Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related
antigens in the rat brain.
European Journal of Neuroscience., 1998 10:1743-1751.
33) Porcella A. Casellas P. Gessa GL. Pani L.
Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the
antiglaucoma properties of marihuana.
Molecular Brain Research, 1998, 58:240-245.
34) Pani L. Porcella A. Gessa GL.,
The role of stress in the pathophysiology of the dopaminergic system.
Molecular Psychiatry, 2000, 5:14-21
35) Porcella A. Maxia C. Gessa GL. Pani L.
The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein.
European Journal of Neuroscience, 2000, 12:1123-1127
36) Pani L.
Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system
and current environmental conditions in industrialized countries?
Molecular Psychiatry, 2000, 5:467-475
37) Ruiu S. Marchese G. Saba PL. Gessa GL. Pani L.
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex
Molecular Psychiatry, 2000, 5:673-677
38) Porcella A. Maxia C. Gessa GL. Pani L.
The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma
resistant to conventional therapies.
European Journal of Neuroscience, 2001, 13:409-412
39) Saba L. Porcella A. Congeddu E. Colombo G. Gessa GL. Peis M. Pistis M. Pani L.
The R100Q mutation of the GABAA 6 receptor subunit may contribute to voluntary aversion to
ethanol in the sNP rat line
Molecular Brain Research, 2001, 87:263-270
40) Devoto P. Flore G. Ibba A. Fratta W Pani L.
Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus
accumbens dopamine release as studies by brain microdialysis.
Toxicology Letters, 2001, 121:199-206.
41) Devoto P. Flore G. Pani L. Gessa G. L.
Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral
cortex
Molecular Psychiatry, 2001, 6:657-664
42) Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L
S(-) Amisulpride binds with high affinity to cloned dopamine D2 and D3 receptors
European Journal of Pharmacology, 2001, 432: 143-147
43) Pani L., Gessa G.L.
The substituted benzamides and their clinical potential on dysthymia and on the negative
symptoms of schizophrenia
Molecular Psychiatry, 2002, 7:247-253
44) Casu MA, Colombo G, Gessa GL, Pani L.
Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 7 / 25
Curriculum Vitae
Luca Pani
Brain Research, 2002, 924:242-251
45) Marchese G, Casu MA, Bartholini F, Ruiu S, Saba PL, Gessa GL, Pani L.
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes
in rat nigro-striatal dopaminergic neurons directly related to `early onset' vacuous chewing
European Journal of Neuroscience, 2002, 15:1-11
46) Marchese G, Bartholini F, Ruiu S, Casti P, Saba PL, Gessa GL, Pani L.
Effect of amisulpride isomers on rat catalepsy
European Journal of Pharmacology, 2002 444:69-76.
47) Porcella A, Marchese G, Casu MA, Rocchitta A, Lai ML, Gessa GL, Pani L.
Evidence for functional CB1 Cannabinoid receptor expressed in the rat thyroid
European Journal of Endocrinology, 2002, 147:255-261
48) Marchese G, Ruiu S, Casti P, Bartholini F, Saba PL, Gessa GL, Pani L.
Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central
effect.
European Journal of Pharmacology, 2002, 447:109-114
49) Marchese G, Bartholini F, Ruiu S, Casti P, Saba PL, Gessa GL, Pani L.
Effect of amisulpride isomers on rat prolactinemia
European Journal of Pharmacology, 2002, 448:263-266.
50) Casu M, Dinucci D, Colombo G, Gessa G, Pani L.
Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats.
Brain Research, 2002, 948 :192-202
51) Pani L., Gessa G.L.
Dopaminergic deficit and Mood Disorders
International Clinical Psychopharmacology, 2002, 17 Suppl 4 : S1-S7
52) Pani L.
Clinical implications of dopamine research in schizophrenia.
Curr Med Res Opin. 2002;18 Suppl 3:s3-7.
53) Koukopoulos A. Sani G. Koukopoulos A.E. Minnai G.P Girardi P. Pani L. Albert M.J. Reginaldi D
Duration and Stability of the Rapid-Cycling Course: A Long-term Personal Follow-Up of 109 Patients
Journal of Affective Disorder, 2003, 73: 75-85
54) Ruiu S., Marchese G., Saba PL., Gessa GL., Vaccari A., Pani L.
In vitro evidence for the presence of [3H]-haloperidol uptake in rat brain.
Br J Pharmacol. 2003, 138:188-192
55) Congeddu E, Saba L, Porcella A, Sanna A, Marchese G, Lobina C, Gessa GL, Pani L.
Molecular characterization of new polymorphisms at the 2, 1, 2 GABAA receptor subunit genes
associated to a rat non-preferring ethanol phenotype.
Brain Res Mol Brain Res. 2003; 110:289-297.
56) Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MA, Reali R, Gessa GL, Pani L.
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract.
Eur J Pharmacol. 2003; 459:97-105.
57) Devoto D., Flore G., Vacca G., Pira L., Arca A., Casu M.A., Pani L., Gessa G.L.
Co-release of noradrenaline and dopamine from neuroadrenergic neurons in the cerebral cortex
induced by clozapine, the prototype atypical antipsychotic.
Psychopharmacol. 2003, 167:79-84.
58) Sanna A, Congeddu E, Porcella A, Saba L, Pistis M, Peis M, Marchese G, Lobina C, Grayson D,
Gessa GL, Pani L.
Characterization of wild-type (R100R) and mutated (Q100Q) GABAA 6 subunit in Sardinian alcohol
non-preferring rats (sNP).
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 8 / 25
Curriculum Vitae
Luca Pani
Brain Res Mol Brain Res., 2003, 967:98-105
59) Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L.
Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid
receptor.
J Pharmacol Exp Ther. 2003, 306: 363-370
60) Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L.
Haloperidol, but not clozapine, produces dramatic catalepsy in Delta9-THC-treated rats: possible
clinical implications.
Br J Pharmacol. 2003, 140:520-526.
61) Marchese G, Bartholini F, Ruiu S, Casti P, Casu G, Pani L.
Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylaseimmunostaining alterations induced by haloperidol
Eur J Pharmacol. 2004, 483: 65-69
62) Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L.
Haloperidol versus risperidone on rat “early onset” vacuous chewing
Behavioural Brain Research 2004, 149: 9-16
63) Casu MA, Pisu C, Lobina C, Pani L.
Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring
rats.
Psychopharmacology (Berl). 2004, 172: 341-351
64) Sanna A, Congeddu E, Saba L, Porcella A, Marchese G, Ruiu S, Casti P, Saba PL, Pani L.
The cerebellar GABAA 6 subunit is differentially modulated by chronic ethanol exposure in normal
(R100R) and mutated (Q100Q) sNP rats.
Brain Res. 2004 998:148-154
65) Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, Ruiu S, Gessa GL.
Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new
ligands of cannabinoid receptors.
Bioorg Med Chem. 2004, 12:1921-1933.
66) Casti P, Marchese G, Casu G, Ruiu S, Pani L.
Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by
haloperidol in mice.
Neuropharmacology. 2004, 47:128-135.
67) Racagni G, Canonico PL, Ravizza L, Pani L, Amore M.
Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology. 2004,
50:134-143. Review.
68) Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B.
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
Psychiatr Serv. 2004 55:997-1005.
69) Pira L, Mongeau R, Pani L.
The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat
prefrontal cortex.
Eur J Pharmacol. 2004 Nov 3;504(1-2):61-4.
70) Tambaro S, Ruiu S, Dessi C, Mongeau R, Marchese G, Pani L.
Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays.
J Pharmacol Exp Ther. 2005 Feb;312(2):710-7.
71) Murineddu G, Ruiu S, Mussinu JM, Loriga G, Grella GE, Carai MA, Lazzari P, Pani L, Pinna GA.
Tricyclic pyrazoles.
Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands
for cannabinoid receptors.
Bioorg Med Chem. 2005 May 2;13(9):3309-20.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 9 / 25
Curriculum Vitae
Luca Pani
72) Saba L, Porcella A, Sanna A, Congeddu E, Marziliano N, Mongeau R, Grayson D, Pani L.
Five mutations in the GABA A alpha6 gene 5' flanking region are associated with a reduced basal and
ethanol-induced alpha6 upregulation in mutated Sardinian alcohol non-preferring rats.
Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):252-7.
73) Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R, Pani L.
Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an
immunohistochemical study.
Brain Res. 2005 Jun 28;1048(1-2):41-7.
74) Caboi F, Lazzari P, Pani L, Monduzzi M.
Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system.
Chem Phys Lipids. 2005 Jun;135(2):147-56.
75) Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S.
Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid
receptors.
Eur J Pharmacol. 2005 Nov 21;525(1-3):150-3.
76) Murineddu G, Ruiu S, Loriga G, Manca I, Lazzari P, Reali R, Pani L, Toma L, Pinna GA.
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the
cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
J Med Chem. 2005 Nov 17;48(23):7351-62.
77) Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessi C, Curzu MM,
Chelucci G, Pani L, Pinna GA.
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective
CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2c]pyrazole-3-carboxamide.
J Med Chem. 2006 Dec 14;49(25):7502-12.
78) Casu MA, Sanna A, Spada GP, Falzoi M, Mongeau R, Pani L.
Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus
accumbens.
Brain Res. 2007, 1141, 15-24
79) Loriga G, Ruiu S, Manca I, Murineddu G, Dessi C, Pani L, Pinna GA
3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6- diazabicyclo[3.1.1]heptanes as novel
potent dopamine uptake inhibitors
Bioorg Med Chem. 2007 Jun 1;15(11):3748-55.
80) Pani L, Pira L, Marchese G
Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. Review.
Eur Psychiatry. 2007 Jul;22(5):267-75. Review.
81) Mongeau R, Marcello S, Andersen JS, Pani L
Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice
Behav Brain Res. 2007 Nov 2;183(2):147-55.
82) Mongeau R, Casu MA, Pani L, Pillolla G, Lianas L, Giachetti A.
Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology
content over the Internet.
Comput Methods Programs Biomed. 2008 May;90(2):124-36.
83) Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.
Practical issues with amisulpride in the management of patients with schizophrenia.
Clin Drug Investig. 2008;28(8):465-77.
84) Marchese G, Sanna A, Casu G, Casti P, Spada GP, Ruiu S, Pani L.
Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or
clozapine administration.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 10 / 25
Curriculum Vitae
Luca Pani
Eur J Pharmacol. 2008 Nov 19;598(1-3):16-20
85) Pani L and Marchese G.
Expected clinical benefits of paliperidone extended-release formulation when compared with
risperidone immediate-release.
Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. Review.
86) Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins.
Sinisi R, Ghilardi A, Ruiu S, Lazzari P, Malpezzi L, Sani M, Pani L, Zanda M.
ChemMedChem. 2009 Sep;4(9):1416-20.
87) Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Olimpieri F, Tambaro S, Fustero S, Lazzari P, Sanchez-Roselló M, Pani L, Volonterio A, Zanda M.
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4715-9.
88) Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting
risperidone administration in rats.
Marchese G, Casu G, Casti P, Spada GP, Pani L.
Eur J Pharmacol. 2009 Oct 12;620(1-3):36-41.
89) Oct4 expression in in-vitro-produced sheep blastocysts embryonic-stem-like cells.
Sanna D., Sanna A., Mara L., Pilichi S., Mastinu A., Chessa F., Pani L., Dattena M.
Cell Biol Int. 2009 Dec 16;34(1):53-60.
90) The need for individualised antipsychotic drug therapy in patients with schizophrenia.
Pani L.
Eur Rev Med Pharmacol Sci. 2009 Nov-Dec;13(6):453-459.
91) A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous
injection of risperidone free-base in rats.
Marchese G, Pittau B, Casu G, Peddio G, Spada GP, Pira M, Deriu A, Portesani F, Pisu C, Lazzari P,
Pani L.
Eur Psychiatry. 2010 Mar;25(2):92-100.
92) 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes
in mice.
Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, de
Novellis V, Malcangio M, Maione S.
Neurobiol Dis. 2010, 37: 177-185
93) Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF
mass spectrometry.
Falzoi M, Mossa A, Congeddu E, Saba L, Pani L.
Pharmacogenomics. 2010 Apr;11(4):559-71.
94) Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.
Lazzari P, Fadda P, Marchese G, Casu GL, Pani L.
Int J Pharm. 2010 Jun 30;393(1-2):238-43. Epub 2010 Apr 23.
95) Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent.
Pisu C, Pira L, Pani L.
96) Weight loss induced by rimonabant is associated with an altered leptin expression and
hypothalamic leptin signaling in diet-induced obese mice.
Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L.
Behav Brain Res. 2011 Mar 1;217(2):432-8. Epub 2010 Nov 11.
97) Unexplained somatic symptoms during major depression: prevalence and clinical impact in a
national sample of Italian psychiatric outpatients.
Perugi G, Canonico PL, Carbonato P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Fornaro
M, Parazzini F, Dumitriu A; Come To Me Study Group.
Psychopathology. 2011;44(2):116-24. Epub 2011 Jan 12.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 11 / 25
Curriculum Vitae
Luca Pani
98) Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across
571 major depressed outpatients.
Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L, Torta R,
Vampini C, Parazzini F, Dumitriu A, Perugi G.
Neuropsychiatr Dis Treat. 2011;7:217-21. Epub 2011 Apr 21.
99) Disclosure of grounds of European withdrawn and refused applications: a step forward on
regulatory transparency.
Tafuri G, Trotta F, Leufkens HG, Pani L.
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424
100) Are "social drugs" (tobacco, coffee and chocolate) related to the bipolar spectrum?
Maremmani I, Perugi G, Rovai L, Maremmani AG, Pacini M, Canonico PL, Carbonato P, Mencacci C,
Muscettola G, Pani L, Torta R, Vampini C, Akiskal HS.
J Affect Disord. 2011 May 21.
101) Novel approaches to drug-placebo difference calculation: evidence from short-term
antidepressant drug-trials.
Rihmer Z, Gonda X, Döme P, Erdős P, Ormos M, Pani L.
Hum Psychopharmacol. 2011 Jul 14. [Epub ahead of print] – I.F. 2.66
102) Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease:
Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations
by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L.
Eur Neuropsychopharmacol. 2011 Sep 6 – I.F. 4.82
103) The placebo arm in clinical studies for treatment of Psychiatric Disorders: a regulatory Dilemma.
Gispen-de Wied C, Stoyanova V, Yu Y, Isaac M, Pani L, de Andres-Trelles F.
Eur Neuropsychopharmacol. 2012 Jun 14 [Epub ahead of print]
104) NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved
molecular profile.
Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P.
Behav Brain Res. 2012 Oct 1;234(2):192-204. doi: 10.1016/j.bbr.2012.06.033. Epub 2012 Jul 4.
105) DSM-5 and clinical trials in psychiatry: challenges to come?
Butlen-Ducuing F, Haas M, Pani L, van Zwieten-Boot B, Broich K.
Nat Rev Drug Discov. 2012 Aug;11(8):583-4. doi: 10.1038/nrd3811.
106) Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using
Molecular Hybridization Based on Scaffold Hopping.
Murineddu G, Asproni B, Ruiu S, Deligia F, Falzoi M, Pau A, Thomas BF, Zhang Y, Pinna GA, Pani L,
Lazzari P.
Open Med Chem J. 2012;6:1-14. Epub 2012 May 17.
107) European licensing of maintenance treatment in schizophrenia.
Isaac M, Pani L, Gispen-de Wied C, Koch A.
Lancet. 2012 Aug 11;380(9841):562-3.
108) Discriminative hypomania checklist-32 factors in unipolar and bipolar major depressive patients.
Perugi G, Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L,
Torta R, Vampini C, Parazzini F, Dumitriu A, Angst J.
Psychopathology. 2012;45(6):390-8. doi: 10.1159/000338047. Epub 2012 Aug 7.
109) Disclosure of grounds of European withdrawn and refused applications: a step forward on
regulatory transparency.
Tafuri G, Trotta F, Leufkens HG, Pani L.
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424
110) Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity
Pani L, Montilla S, Pimpinella G, Bertini Malgarini R.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 12 / 25
Curriculum Vitae
Luca Pani
Expert Opin Biol Ther. 2013 Jun 28. [Epub ahead of print]
111) High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From
the Italian Medicines Agency (AIFA).
Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P, Lapi F, Marchionni N, Pani L, Pecorelli S,
Sancarlo D, Scuteri A, Trifirò G, Vitale C, Zuccaro SM, Bernabei R, Fini M; the Geriatrics Working
Group of the Italian Medicines Agency (AIFA).
J Gerontol A Biol Sci Med Sci. 2013 Aug 2. [Epub ahead of print]
112) Regulatory evaluation of Glybera in Europe - two committees, one mission.
Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I,
Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL,
Salmonson T, Schneider CK.
Nat Rev Drug Discov. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. Epub 2013 Aug 19.
113) Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation
information).
Calizzani G, Vaglio S, Vetrugno V, Delbò M, Pani L, Grazzini G.
Blood Transfus. 2013 Oct 2:1-6. doi: 10.2450/2013.0035-13. [Epub ahead of print]
Chapters in Book:
1) Rossetti Z.L.; Pani L. ; Portas C. ; Carboni S. ; Gessa G.L.
Evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex in The
Basal Ganglia III,
Bernardi et al. Eds., 1990
2) Tondo L; Pani PP; Pani L; Carcassi L; Manconi PE; Rudas N.
T-Lymphocite in depression in: The modes of depression: from psychobiology to psychodynamics.
Ravizza, Genazzani,
Torta and Eva eds. Cortina. Torino, 1990
3) Costa E., Cheney D.L., Grayson D.R., Korneyev A., Longone P., Pani L., Romeo E.,
Zivkovich E., Guidotti A.
Pharmacology of Neurosteroids Biosynthesis: Role of the Mitochondrial DBI receptor (MDR) complex.
In Brain Corticosteroid Receptors : Studies on the Mechanism, Function, and Neurotoxicity of
Corticosteroid Action.
Vol. 746 of The Annals of the New York Academy of Sciences, 1994, 223-242
4) Serra G., Pani L., Collu M, Gessa G.L.
Ruolo delle Monoamine nella patogenesi dei disturbi dell’umore. In La depressione nel bambino e
nell’adolescente.
G. Lanzi et al. (eds) 1994, 179-192
5) Koukopoulos A.,Reginaldi D.,Minnai G., Serra G., Pani L., Johnson FN
The Long Term Prophylaxis of Affective Disorders in Depression and Mania: from Neurobiology to
Treatment,
Gessa GL, Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 127-147
6) Gessa G.L., Pani L., Serra W., Fratta W
Animal Models of Mania in Depression and Mania: from Neurobiology to Treatment,
Gessa G.L., Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 43-67
7) Gessa G.L., Serra G., Pani L.
Biochimica della Distimia : il ruolo della dopamina
Nuova Rivista di Neurologia, Suppl Vol. 5, 10-18 (1995)
8) Pani L., Gessa G.L.
The role of dopamine in the biological basis of dysthymia in Dysthymia in neurological disorders,
Proceedings of the WHO Meeting, J. Licinio; L. Prilipko and C.L. Bolis (eds), WHO Geneva,
Switzerland, 1997.
9) Pani L., Porcella A. and Gessa G.L.
Stress and the dopaminergic System in Stress and the nervous system, Proceedings of the WHO
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 13 / 25
Curriculum Vitae
Luca Pani
Meeting,
J. Licinio and C.L. Bolis (eds), WHO Athens, Greece, 1998.
10) Serra G., Pani L., Gessa G.L.
Clozapina Enciclopedia Medica Italiana, Agg. II, Tomo I, 1284-1288, 1998
11) Pani L., Porcella A. and Gessa G.L.
Dysthymia: Psychosocial Aspects. in Dysthymia in Public Health, Proceedings of the Joint
WHO/AIREN Meeting,
J. Licinio and C.L. Bolis (eds), WHO Geneva, Switzerland, In press, 1999.
12) Pani L., Porcella A, Gessa G.L.
Hypothesis testing: dopaminergic system, environmental pressure and evolutionary mismatch, in
Dopaminergic System:
Evolution from Biology to Clinical Aspects,
Bolis CL, Pani L and Licinio J. (eds) Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
13) Gessa G.L., Pani L, Devoto P
Is dopamine in the prefrontal cortex released from noradrenergic neurons? in
Dopaminergic System: Evolution from Biology to Clinical Aspects, Bolis CL, Pani L and Licinio J. (eds)
Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
14) Pani L, Biggio G
Effetti collaterali delle benzodiazepine in Benzodiazepine dalle molecole alla pratica clinica,
Biggio G, (ed), Springer-Verlaag Italia, Milano 2001
15) Canali S, De Anna G, Pani L
Evolutionary Psychopharmacology mental disorders and ethical behaviour in:
Evolutionary ethics and contemporary Biology, Boniolo G, (ed) Cambridge University Press
Cambridge, 2006
16) Pani L, Saba L
Farmacogenetica degli Antipsicotici in:
Trattato Italiano di Psichiatria, Cassano GB (ed), Masson-Elsevier, Milano 2008
17) Salloum IM, Pani L, Cooke T
Management of Comorbidity in Bipolar Disorder in:
Bipolar Disorder: Clinical and Neurobiological Foundations, Edited by Lakshmi N. Yatham and Mario
Maj, John Wiley & Sons, 2010
Books:
1) Gian Luigi Gessa e Luca Pani
Il ruolo della dopamina nei disturbi depressivi Parte Prima: Neurobiologia della Distimia: il ruolo della
dopamina.
Mediserve Milano, 1998 (I edizione)
2) Luca Pani e Gian Luigi Gessa
Il ruolo della dopamina nei disturbi depressivi Parte Seconda Distimia: diagnosi e trattamento.
Mediserve Milano, 1998 (I edizione)
3) Gian Luigi Gessa e Luca Pani
Il ruolo della dopamina nei disturbi depressivi. Volume Unico
Mediserve Milano, 1999 (II edizione)
4) Gerardo Medea e Luca Pani
I Disturbi depressivi in Medicina Generale. Diagnosi e Gestione
UTET Periodici Milano, 2000
5) Luca Pani
La Biochimica del Cervello
Masson, Milano 2001
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 14 / 25
Curriculum Vitae
Luca Pani
6) Stefano Canali e Luca Pani
Emozioni e malattia. Dall’evoluzione biologica al tramonto del pensiero psicosomatico
Paravia Bruno Mondadori Editori, Milano 2003
7) Luca Pani
Distimia: dal temperamento alla malattia
Masson, Milano 2004
8) Luca Pani
La Rivoluzione di Paul Janssen
Cinquant’anni di Terapia della Schizofrenia: dall’aloperidolo al paliperidone
Elsevier, Milano 2009
Editor of Books:
1) Depression and Mania: from Neurobiology to Treatment,
Gessa GL, Fratta W., Pani L and Serra G. (eds),
Raven Press, New York, 1995
2) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
I Edizione Italiana a cura di: Luca Pani e Gian Luigi Gessa, Centro Scientifico Editore, Torino, 1999
3) Dopaminergic System: Evolution from Biology to Clinical Aspects
Bolis CL, Pani L and Licinio J. (eds)
Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
4) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
II Edizione Italiana a cura di: Luca Pani e Gian Luigi Gessa, Centro Scientifico Editore, Torino, 2002
5) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
III Edizione Italiana a cura di: Luca Pani, Edi-Ermes, Milano, 2011
6) Depressione e Disturbi Bipolari estratto da Psicofarmacologia Essenziale, Basi Neuroscientifiche e
Applicazioni Pratiche di Stephen M.Stahl; Ediz. Italiana a cura di: Luca Pani, Edi-Ermes Milano 2011
International (IN RED) or National Consultation/Advisory Boards, Invited Lectures, Teaching and
Presentation at Continuous Medical Education Courses (CME).
Projects
Luca Pani is one of the inventors (does not have ownership) of two new U.S. and one E.C. Patents
namely:
US2010029622A1 (Feb, 4 – 2010) on Microemulsion
US2010028257A1 (Feb, 4 – 2010) on Novel Omepiperazines Opioids
EP2223681A1 (Feb, 24 - 2010) on Composition of spores of non pathogenic bacteria
Memberships
Since 1994, Luca Pani has been invited to give presentation in more than 1000 Conferences,
Seminars, Expert Opinion, Round Tables etc etc. Please note the following events:
Member of Educational / Editorial Strategic Boards: not product specific and open to delegates
primarily health care professionals and organized though a provider of medical education to
pharmaceutical companies
Speaker in Medical Education Events : such events were not product specific, open to all delegates
(healthcare professionals), without restriction, and focused on psychopharmacology (animal models,
relationship between PK profiles and clinical impact).
I was involved as a paid speaker in some of these events, and in some cases the participation was
together with other experts in the field.
Jan 14, 2009 Rome (I) Meeting on Neurobiology of Depression Project
Jan 19, 2009 Milan (I) CME Sanofi Aventis Strategic Board on CNS Drugs
Jan 20, 2009 Milan (I) CME Janssen Meeting on Tolerability
Jan 23, 2009 Cagliari (I) University of Cagliari. Lecturer in Psychiatric Rehabilitation Course
Jan 26, 2009 Milan (I) San Raffaele University. Lecturer Master in Psychopharmacology
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 15 / 25
Curriculum Vitae
Luca Pani
Jan 28, 2009 Catania (I) New Formulations for New Antipsychotics. AILAS National Conference.
Feb 11, 2009 Rome (I) Italian Congress of Psychopathology. The INVERITAS Tool for Continuous
Medical Education in Psychiatry.
Feb 12, 2009 Rome (I) Italian Congress of Psychopathology. Why we don’t have new drugs in
psychopharmacology?
Feb 12, 2009 Rome (I) Italian Congress of Psychopathology. Quetiapine-XR Pharmacological Profile
and Clinical Implications
Feb 12, 2009 Rome (I) Italian Congress of Psychopathology. Neuroplasticity and Psychodrugs: Myth
or Reality?
Feb 13, 2009 Rome (I) Italian Congress of Psychopathology. The importance of First Episode in
Schizophrenia and Bipolar Disorders(CHAIR)
Feb 13, 2009 Rome (I) Italian Congress of Psychopathology. A unique pharmacological fingerprint:
Ziprasidone.
Feb 17, 2009 Florence (I) Symposium for Quetiapine-XR. Pharmacological Basis of Quetiapine-XR
Clinical Effect.
Feb 19, 2009 Rome (I) INVERITAS Tool a new platform for the education in the treatment of
psychoses. (CHAIR and Scientific Coordinator)
Feb 20, 2009 Florence (I) Question Time in Psychiatry 2009. CME
Feb 24, 2009 Bolzano (I) Question Time in Psychiatry 2009. CME
Feb 25, 2009 Rome (I) Round Table on Clinical Experience in Antipsychotic Efficacy Elite Project.
(CHAIR and Scientific Coordinator)
Feb 26, 2009 Florence (I) Improving PK-PD of Antipsychotics for a better outcome. Symposium on the
Antipsychotics in Spectrum Disorders
Feb 27, 2009 Venice (I) Question Time in Psychiatry 2009. CME
Mar 9, 2009 Parma (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR, Scientific
Coordinator, Speaker)
Mar 10, 2009 Castel Gandolfo (I) La Neurobiologia della Depressione. Risvolti Clinici. CME
Mar 11, 2009 Grotta Ferrata (I) La Neurobiologia della Depressione. Risvolti Clinici. CME
Mar 13, 2009 Taipei (Taiwan) Antipsychotic at D2 receptor: where and how. Yuli Hospital, Department
of Health, Taiwan
Mar 14, 2009 Tainan (Taiwan) Antipsychotic at D2 receptor: where and how. National Cheng Kung
University, Taiwan
Mar 15, 2009 Kaohsiung (Taiwan) Antipsychotic at D2 receptor: where and how. Kaohsiung Medical
University, Taiwan
Mar 16, 2009 Taipei (Taiwan) Antipsychotic at D2 receptor: where and how. National Taiwan
University, Taiwan
Mar 16, 2009 Taipei (Taiwan) Antipsychotic at D2 receptor: where and how. Taipei City Psychiatric
Center, Taiwan
Mar 17, 2009 Taipei (Taiwan) Antipsychotic at D2 receptor: where and how. National Yang-Ming
University and Taipei Veterans General Hospital, Taiwan.
Mar 19, 2009 Frascati (I) La Neurobiologia della Depressione. Risvolti Clinici. CME
Mar 24, 2009 Catanzaro (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
Mar 25, 2009 Bolzano (I) Question Time in Psychiatry. CME Course.
Mar 26, 2009 Bolzano (I) Question Time in Psychiatry. CME Course.
Mar 27-28, 2009 Berlin (D) Mind Matters, 10th Internationa Forum on Mental Disorders, Keynote
Speaker and Chair
Mar 30, 2009 Bolzano (I) Question Time in Psychiatry. CME Course
Apr 1, 2009 Florence (I) World Psychiatric Association. New Models of Delivery of Antipsychotic drugs
Apr 3, 2009 Florence (I) World Psychiatric Association. Modifying the pharmacokinetic and
pharmacodynamic properties of antipsychotic for improved outcomes
Apr 3, 2009 Florence (I) Eplivanserin Scientific Board
Apr 5, 2009 Bormio (I) Update Conference. Psicosi come Malattie Complesse: suggestioni dal
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 16 / 25
Curriculum Vitae
Luca Pani
Sistema Immunitario.
Apr 9, 2009 Florence (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
Apr 20, 2009 Cagliari (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR, Scientific
Coordinator, Speaker)
Apr 21, 2009 Genoa (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR, Scientific
Coordinator, Speaker)
April 22, 2009 Savona (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
April 28, 2009 Milan (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific Coordinator
May 5, 2009 Milan (I) CME Janssen International Core Faculty Meeting on Tolerability (Chair and
Speaker)
May 7, 2009 Palermo (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
May 11, 2009 Cagliari (I) European Master in Plant Therapy: The Design of a Clinical Trial and related
Drug Development.
May 12, 2009 Rome (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
May 14, 2009 Gazzo Padovano (I) INVERITAS CME Course. Antipsychotics in Schizophrenia
(CHAIR, Scientific Coordinator, Speaker)
May 15, 2009 Gazzo Padovano (I) Prolactine and Antipsychotics: Status of the literature and Clinical
Management
May 20, 2009 Rome (I) Ziprasidone pharmacological Profile Meeting
May 21, 2009 Cagliari (I) School of Specialty in Psychiatry. Faculty of Medicine University of Cagliari.
Course on Psychobiology (Chair).
May 22, 2009 Cagliari (I) University of Cagliari. Lecturer in Psychiatric Rehabilitation Course
May 25, 2009 Lamezia Terme (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR,
Scientific Coordinator, Speaker)
May 26, 2009 Perugia (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
May 27, 2009 Naples (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
May 28, 2009 Milan (I) Scientific Board on Eplivanserine.
May 29, 2009 Alghero (I) National Conference on Forensic Psychiatry. Pharmaceutical formulations of
Antipsychotics:have experimental results any clinical significance?
June 3, 2009 Folignano (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR,
Scientific Coordinator, Speaker)
June 4, 2009 Grottaferrata (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR,
Scientific Coordinator, Speaker)
June 5, 2009 Verona (I) CME Course. Villa Santa Chiara. Research & Development in
Psychopharmacology: are we wide at sea or do we see land?
June 6, 2009 Lisbon (P) International Meeting, Scientific Committee, Chair and Speaker: What impact
do antipsychotic formulations have on your treatment choices?
June 8, 2009 Palermo (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR,
Scientific Coordinator, Speaker)
June 9, 2009 Padova (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
June 11, 2009 Bari (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR, Scientific
Coordinator, Speaker)
June 12, 2009 Bari (I) Identities and Differences in Antipsychotics Drug Development and Clinical
Responses
June 16, 2009 Alessandria (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
June 17, 2009 Gazzada (I) INVERITAS CME Course. Antipsychotics in Schizophrenia (CHAIR,
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 17 / 25
Curriculum Vitae
Luca Pani
Scientific Coordinator, Speaker)
June 18, 2009 Gazzada (I) New Antipsychotics for New Treatment Expectation
June 30, 2009 Cagliari (I) School of Specialty in Psychiatry. Faculty of Medicine University of Cagliari.
Course on Psychobiology (Chair).
July 2, 2009 Cagliari (I) Regione Autonoma della Sardegna. Assessorato alla Programmazione.
Scientific Research Committee Meeting.
July 3, 2009 Ancona (I) Congresso Nazionale: Gli Antipsicotici. Efficacia degli antipsicotici in relazione
ai recettori D2.
July 8, 2009 Rome (I) Italian Medicines Agency (AIFA). Committee on Clinical Neuroscience
Sept 10, 2009 Foggia (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
Sept 11, 2009 Instanbul (TK) European Neuropsychopharmacolgy (ECNP) Annual Congress.
Sept 23, 2009 Korneberg (B) Master Class. Antipsychotics from Drug Development to Clinical
Outcomes. Catholic University of Leuven, Dept. of Psychiatry, St. Joseph Hospital
Sept 29, 2009 Cagliari (I) School of Specialty in Psychiatry. Faculty of Medicine University of Cagliari.
Course on Psychobiology (Chair).
Oct 3, 2009 Cagliari (I) Modern Pharmacology for the Aging Brain. Conference on Depression and
Dementia
Oct 5, 2009 Arezzo (I) Approccio Farmacologico alla terapia antipsicotica negli SPDC.
Oct 8-9, 2009 Pula (I) 1)Presentation of a Center of Excellence: The case of PharmaNess2)PK-PD of
Antipsychotics for improved outcomes. Conference: Descartes’ Error (Scientific Board and Chair)
Oct 13, 2009 Rome (I) From Mania to depressive symptoms: beyond the antipsychotic action of
drugs. XLV Conference of the Italian Society of Psychiatry. National Congress.
Oct 16, 2009 Rimini (I) Pharmacological Characteristics of Ziprasidone: Advices to Clinicials. XXXIV
Conference of the Italian Society of Pharmacology. National Congress.
Oct 20, 2009 Cesena (I) Second Life in Schizoprenia. CME Course. Speaker and Scientific
Coordinator
Oct 21, 2009 Massa Lubrense (I) Choosing the Antipsychotic in the acute phase of Schizophrenia and
Bipolar Disorder. What you have to consider. (with Andreas Erfurth). Meeting: I tempi delle terapia
antipsicotica: modulare la terapia lungo le fasi del disturbo e le necessita’ del paziente.
Oct 22, 2009 Massa Lubrense (I) New Vistas in the Neurobiology of Schizophrenia and Bipolar
Disorder: implication for therapy. (with Andrea De Bartolomeis). Meeting: I tempi delle terapia
antipsicotica: modulare la terapia lungo le fasi del disturbo e le necessita’ del paziente.
Oct 23, 2009 Madrid (E) Expected clinical benefits of paliperidone extended-release formulation when
compared with risperidone immediate-release. XIII Spanish National Conference of Psychiatry.
Nov 5, 2009 Modena (I) From the Art of Psychopharmacology to the Status of the Art. Meeting: Eppur
si muove. La farmacoterapina in psichiatria tra successi, delusioni e speranze.
Nov 6, 2009 Viareggio (I) The “Idea” of God, an Ethological, Psychological and Psychopathological
Perspective
Nov 7, 2009 Florence (I) Ziprasidone. Aspetti farmacologici
Nov 9,2009 Naples (I) Antipsicotici di II generazione: aspetti farmacologici
Nov 12, 2009 Cagliari (I) Fase 1 srl: Genesi, attualità, futuro
Nov 14, 2009 Acapulco (MEX) Mexican Psychiatry Association Congress - Interactive clinical cases in
Schizophrenia
Nov 17, 2009 Barcellona (E) Meeting Switch Study
Nov 18, 2009 Vicenza (I) Antipsicotici a confronto: criteri di scelta nell'utilizzo degli antipsicotici di
nuova generazione
Nov 20, 2009 Cagliari (I) Neurobiologia delle malattie mentali: un breve sommario
Nov 23, 2009 Bruxelles(B) PK/PD IV Core Faculty Meeting (Chair and Speaker)
Nov 27, 2009 San Gimignano (I) Efficacia, effetti collaterali, interazioni farmacologiche di bupropione
Nov 28, 2009 Cagliari (I) Trattamento antipsicotico. Nuove evidenze per una corretta gestione del
paziente schizofrenico
Dec 1, 2009 Naples (I) International Conference: “Bipolar Depression. New Therapeutical
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 18 / 25
Curriculum Vitae
Luca Pani
Perspectives”
Dec 5, 2009 Thessaloniki (GR) 4th international congress on brain e behaviour - " What impact do
antipsychoctic formulations have on your treatment choices?"
Jan 25, 2010 Rome (I) Italian Medicines Agency (AIFA). Committee on Clinical Neuroscience
Feb 2, 2010 Cagliari (I) Design and Future of Clinical Trial, Regional Meeting of Italian Society of
Hospital Pharmacists (SIFO)
Feb 5-6, 2010 Vienna (A) Faculty Update Meeting. Scientific Coordinator, Speaker and Chair
Feb 7, 2010 Dubai (UAE) Al Rashid Hospital Pharmaceutical Formulations of antipsychotics and
clinical outcomes
Feb 8, 2010 Riyadh (KSA) Military Hospital Discussion of Clinical Cases.
Lecture on Pharmaceutical Formulations of antipsychotics and clinical outcomes
Feb 9, 2010 Jeddah (KSA) Military Hospital Discussion with Psychiatric Residents.
Lecture on Pharmaceutical Formulations of antipsychotics and clinical outcomes
Feb 10, 2010 Al-Khobbar (KSA) Royal University Grand round table and clinical cases discussion
Feb 11, 2010 Al-Khobbar (KSA) Royal University Lecture on Pharmaceutical Formulations of
antipsychotics and clinical outcomes
Feb 16, 2010 Rome (I) Presentation of Progetto UOMO (Phase-I; Man simulator Algorithm) with Dr.
Patricia Rodriguez-Tome’
Feb 17, 2010 Rome (I) Italian Society of Psychopathology National Conference:
Why Paliperidone-ER is different from Risperidone
Feb 18, 2010 Rome (I) Italian Society of Psychopathology National Conference:
Bipolar disorder: the biological basis of clinical evidence
Feb 19, 2010 Rome (I) Italian Society of Psychopathology National Conference:
New frontiers in antipsychotics development
March 1-4, 2010 Venice (I) Question Time in Psychiatry: new perspective in bipolar depression
therapy. (Speaker and Chair)
March 5-6, 2010 Castelbrando (I) Evolution in new criteria of choice in antipsychotic therapy (Speaker
and Chair)
March 10, 2010 Massa-Lubrense (I) The “Times” of antipsychotic therapy: modulation of treatment
along the phases of the disorder.
March 15-19, 2010 Venice (I) Question Time in Psychiatry: new perspective in bipolar depression
therapy. (Speaker and Chair)
March 24, 2010 Cagliari (I) Regional Committee on Scientific Research (Gov. of Sardinia)
March 25, 2010 Rome (I) School of Excellence Conference: Antipsychotics and Antidepressant
common lives divergent fates.
March 27, 2010 Busan (KR) Next IV Asia-Pacific Symposium: Why are paliperidone-ER and
risperidone different?
March 28, 2010 Asan Medical Center Seoul (KR) Grand Round and meeting with Psychiatric
Residents. Lecture: New animal models in antipsychotic development: a contribution to clinicial
March 29, 2010 SamSung Medical Center Seoul (KR) Grand Round and meeting with Psychiatric
Residents.Lecture: New animal models in antipsychotic development: a contribution to clinicial
April 16-17, 2010 Portofino (I) Zip-ALGO Evolution of the choice criteria for antipsychotics
April 21, 2010 Cagliari (I) Regional Committee on Scientific Research (Gov. of Sardinia)
May, 17-18, 2010 London (UK) CHMP Meeting European Medicine Agency
May 25, 2010 Pula (I) Drug Discovery in a European Perspective
May 27, 2010 Verona (I) Psychosis and Cognitive Domains
May 28, 2010 Montegridolfo (I) Bipolar Disorder and Schizophrenia new drugs for both?
June 16, 2010 Siena (I) 1) Criteria of choices for antipsychotics in schizophrenia and bipolar disorder
2) Antipsychotics, what clinicians should know
June 18, 2010 Beirut (LB) 1) How changes in atypical antipsychotic formulations can affect clinical
outcomes 2) Mechanism of action of Antipsychotics: from statical animal model to complex dynamics.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 19 / 25
Curriculum Vitae
Luca Pani
A contribution to the Clinicians
June, 21-24, 2010 London (UK) CHMP Meeting European Medicine Agency
June 25, 2010 Rome (I) Italian Medicines Agency – I Expert Meeting
July 1, 2010 Rome (I) Italian Medicines Agency – Drug Company Meeting: BMS; GSK (Scientific
Support)
July 2, 2010 Frascati (I) Minor Depression in the Elderly – An introduction
July 8, 2010 Rome (I) 1) PDCO – Vitero Meeting European Medicine Agency 2) Italian Medicines
Agency – II Expert Meeting
July 12, 2010 Catania (I) 1) Can Long acting antipsychotics boost treatment adherence, is it true? 2)
New Antipsychotics drug discovery and development International School of Neuroscience
July 19, 2010 Copenhagen (DK) Pharmacokinetics and Pharmacodynamics of Antipsychotics XIth
World Conference of Basic and Clinical Pharmacology 2010: WorldPharma2010
July 20-22, 2010 London (UK) CHMP Meeting European Medicine Agency
July 30, 2010 Rome (I) AIFA Director General Meeting on a new model for Enviromental risk of drugs
August 2, 2010 London by TC VITERO Meeting Non Clinical Working Group for the Paediatric
Committee (PDCO) European Medicine Agency
August 4, 2010 Rome (I) AIFA Meeting of CHMP Rapp/Co-Rapp Products
August 27-28, 2010 Amsterdam (NL) 23rd European College of Neuropsychopharmacology (ECNP)
Congress, Scientific Advisory Panel (SAP) Target Expert Meeting (TEM) on Antipsychotics
August 30, 2010 Amsterdam (NL) Optimal outcomes for patients with schizophrenia: a focus on
functioning23rd European College of Neuropsychopharmacology (ECNP) Congress
Sept. 1, 2010 Bejing (CN) Optimal outcomes for patients with schizophrenia: a focus on
functioningWPA Regional Meeting, Psychiatry Medical Congress, Presentation
Sept. 2, 2010 Bejing (CN) Guiding antipsychotics prescription from receptor dynamics to functional
outcome Psychiatry live Webcast Meeting
Sept. 3, 2010 Bejing (CN) New drug delivery models: how do they improve antipsychotics benefit/risk
ratio? Psychiatric Chinese Society, Local Meeting
Sept. 4, 2010 Taipei (TW) Mechanism of action of antipsychotics: from statical animal model to
complex dynamics. A contribution to the Clinicians
Sept. 5, 2010 Keohsiung (TW) Mechanism of action of antipsychotics: from statical animal model to
complex dynamics. A contribution to the Clinicians
Sept. 6, 2010 London by TC Rasival TC-CHMP, European Medicine Agency
Sept. 8, 2010 London (UK) Extra CHMP (Avandia, Pandemrix) , European Medicine Agency
Sept 13, 2010 Rome (I) AIFA Meetings, TC (London) on Control Arm Paper Company Meeting on
Cupyrima
Sept 16, 2010 Rome (I) AIFA Meetings, CHMP Preparation
Sept 17, 2010 Viterbo (I) INVERITAS 2010 CME Course. Algorithms in Schizophrenia Treatment
(CHAIR, Scientific Coordinator, Speaker)
Sept 20-22, 2010 London (UK) CHMP Meeting European Medicine Agency
Sept 24, 2010 am Cagliari (I) Gli outcome ottimali per il paziente schizofrenico: focus sul
funzionamento XVII Congresso Nazionale della Società Italiana di NeuroPsicoFarmacologia
Sept 24, 2010 pm Cagliari (I) Regional Committee on Scientific Research (Gov. of Sardinia)
Sept 25-27, 2010 Cagliari (I) Fase 1 srl: Board Meeting
Sept 27 (pm)-29, 2010 Gardone Riviera (I) Schizophrenia: Outcome, Functioning, Adherence (SOFA
program)
Oct 1, 2010 Carpi (I) Antipsychotics: clinical criteria for switching
Oct 4, 2010 London (UK) WPCNS Meeting, European Medicine Agency
Oct 5-6, 2010 Al-Khobbar (KSA) A. Treatment resistant schizophrenia B. Antipsychotics in Bipolar
disorders First Saudi Arabia Conference on Psychiatry
Oct 7, 2010 Rome (I) Università la Sapienza. Lecture on Neurobiological Basis and
Psychopharmacology of Schizophrenia
Oct 11, 2010 Rome by TC CHMP – ORGAM Meeting @ AIFA
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 20 / 25
Curriculum Vitae
Luca Pani
Oct 11, 2010 Rome (I) Meeting at AIFA with Dr. Margareth Hamburg (FDA Commissioner)
Oct 12-14 2010 Rome (I) Italian Medicines Agency (AIFA). Pre-CHMP Meeting
Oct 14, 2010 Rome (I) Italian Medicines Agency (AIFA). Scientific Advice Meeting (RB-Company)
Oct 15, 2010 S.Ippolito (I) INVERITAS 2010 CME Course. Algorithms in Schizophrenia Treatment
(CHAIR, Scientific Coordinator, Speaker)
Oct 18-21, 2010 London (UK) CHMP Meeting European Medicine Agency
Oct 26, 2010 Miami (USA) Doc Prep for Appointment Dept of Psychiatry and Behavioural Science,
School of Medicine, University of Miami, FL. USA
Oct 30, 2010 Copenhagen (DK) Stand Alone Event on How to improve the clinical outcome in patients
with Schizophrenia. European CME Event. Speaker and Chair
Nov 20-22, 2010 London (UK) CHMP Meeting European Medicine Agency
Nov 30- Dec 1st, 2010 London (UK) SAWP Meeting European Medicine Agency
Dec 13-16, 2010 London (UK) CHMP Meeting European Medicine Agency
Jan 17-20, 2011 London (UK) CHMP Meeting European Medicines Agency
Jan 24, 2011 Rome (I) Trainining to Mentors: Teaching with Algorithms The INVERITAS 2011 Project
Jan 25, 2011 Arcugnano (VI) CME course: Evoluzione e traiettorie della Schizofrenia e del Disturbo
Bipolare: uso degli antipsicotici
Jan 31- Feb 1, 2011 London (UK) SAWP Meeting European Medicines Agency
Feb 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
Feb 10-11 2011 Pula (I) Center of Excellence Meeting (Chair and Speaker)
Feb 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
March 2–4, 2011 London (UK) SAWP Meeting European Medicines Agency
March 5, 2011 Nice (FR) ECNP-EMA Assessor Meeting
March 6-7 2011 Nice (FR) ECNP-EFPIA Summit Meeting
March 10-11, 2011 Pula (I) Center of Excellence Meeting (Chair and Speaker)
March 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
March 23, 2011 Sorrento (I) CME course: Evoluzione e traiettorie della Schizofrenia e del Disturbo
Bipolare: uso degli antipsicotici
March 24-25, 2011 Siena (I) ME Course: Zipswitch Algorithm on how to switch between antipsychotics
March 28-30, 2011London (UK) SAWP Meeting European Medicines Agency
April 4, 2011 London (UK) CNSWP Plenary Meeting
April 11-14, 2011 London (UK) CHMP Meeting European Medicines Agency
April 26-28, 2011London (UK) SAWP Meeting European Medicines Agency
May 16-19, 2011London (UK) CHMP Meeting European Medicines Agency
May 23-26, 2011 London (UK) SAWP Meeting European Medicines Agency
June 20-22, 2011London (UK) CHMP Meeting European Medicines Agency
June 27-30, 2011London (UK) SAWP Meeting European Medicines Agency
July 1, 2011London (UK) Tapestry Network Alliance for Alzheimer
July 12, 2011London by TC CNSWP Meeting European Medicines Agency
July 14-15, 2011 Rome (I) AIFA Study Section on Independent Research
July 18-20, 2011 London (UK) CHMP Meeting European Medicines Agency
Aug 30–31, 2011 London (UK) SAWP Meeting European Medicines Agency
Sep 1, 2011 Paris (FR) Symposium on Human Motivation (Speaker)
Sep 2, 2011 London (UK) Extra-CHMP Meeting European Medicines Agency
Sep 9, 2011 Miami (USA) University of Miami School of Medicine – Lecture Psychiatric Residents
Sep 16, 2011 Miami (USA) University of Miami School of Medicine – Lecture Psychiatric Residents
Sep 19-22, 2011 London (UK) CHMP Meeting European Medicines Agency
Sep 22, 2011 London (UK) CNSWP Meeting European Medicines Agency
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 21 / 25
Curriculum Vitae
Luca Pani
Sep 23, 2011 London (UK) DSM-5 Meeting European Medicines Agency with FDA (Speaker and
Chair)
Sep 26-28, 2011 London (UK) SAWP Meeting European Medicines Agency
Oct 3, 2011 Rome by TC Fase 1 Comitato Tecnico Scientifico
Oct 5, 2011 London (UK) Head Medicines Agency Informal Board Meeting at EMA
Oct 6, 2011 London (UK) Management Board Meeting of EMA
Oct 13-14, 2011 Rome (I) TOPRA Meeting
Oct 17-18, 2011 London (UK) CHMP Meeting European Medicines Agency
Oct 24-27, 2011 London (UK) SAWP Meeting European Medicines Agency
Nov 14, 2011 Rome (I) Fase 1 – Comitato Tecnico Scientifico
Nov 14-17, 2011 London (UK) CHMP Meeting European Medicenes Agency
Nov 28-30, 2011 London (UK) SAWP Meeting European Medicines Agency
Dec 12-14, 2011 London (UK) CHMP Meeting European Medicines Agency
Dec 15 2011 London (UK) Management Board Meeting of EMA
Dec 19 2011 Rome (I) Fase 1 – Comitato Tecnico Scientifico
Jan 20, 2012 Rome (I) Simposio Internazionale: The biopolar spectrum from somatic illness to manicdepressive illness
Jan 23 2012 Rome (I) Fase 1 – Comitato Tecnico Scientifico
Jan 30- Feb 2, 2012 London (UK) SAWP Meeting European Medicines Agency
Feb 14, 2012 Rome (I) Promuovere la Medicina Traslazinale attraverso le infrastrutture dedicate alla
Salute e alla Ricerca
Feb 23-24, 2012 Copenhagen (DK) Heads of Medicines Agencies Meeting (HMA)
Feb 27 – March 2,2012 London (UK) SAWP Meeting European Medicines Agency
March 8, 2012 Rome (I) Comitato Tecnico Scientifico
March 12-15, 2012 London (UK) CHMP Meeting European Medicines Agency
March 21-22, 2012 London (UK) Management Board Meeting of EMA
April 2, 2012 Rome (I) Secondo Seminario di Alta formazione in preparazione sanitaria su: analisi
delle caratteristiche e della demografia del personale del Servizio Sanitario Nazionale
April 17, 2012 Rome (I) Seminario del Forum per la Ricerca Biomedica sull'innovazione e la ricerca in
campo sanitario e farmacologico
April 23-26, 2012 London (UK) SAWP Meeting European MedicinesAgency
May 10, 2012 Rome (I) About Pharma Focus on Farmaci Generici e innovatività: tra sostenibilità e
sviluppo
May 10-11, 2012 Rome (I) HTA e decision making
May 11, 2012 Rome (I) Fase 1 – Comitato Tecnico Scientifico
May 23, 2012 Geneva (CH) Seminario Sanitary Regulation - challenges in a world without borders:
improving cooperation Drug Regulatory Agencies - WHO
May 25, 2012 Chia Laguna (I) 5° Forum Nazionale SIF
May 28-29, 2012 London (UK) SAWP Meeting European Medicines Agency
May 31-June 1, 2012 Rimini (I) 52° Simposio Annuale AFI
June 19-20, 2012 Copenhagen Heads of Medicines Agencies Meeting (HMA)
June 21-22, 2012 Rome (I) Generici e Biosimilari
June 25-28, 2012 Philadelphia (USA)DIA Annual Meeting
July 2, 2012 (I) Round table I-com Juy 3, 2012 Rome (I) 4° Convegno Nazionale della Public Affairs
Association
July 5, 2012 Rome (I) Convegno Analisi della prescrizione farmaceutica in Italia
August 20-23, 2012 London (UK) SAWP Meeting European Medicines Agency
September 20-21, 2012 Cyprus Heads of Medicines Agencies Meeting (HMA)
October 7, 2012 Milan (I) 46° Congresso Nazionale SIP
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 22 / 25
Curriculum Vitae
Luca Pani
October 9, 2012 Rome (I) Roundtable – Le prospettive del Princing del Farmaco in Italia(I-COM)
October 11-14, 2012 Bari (I) XXXIII Congresso Nazionale SIFO
October 22-24, 2012 London (UK) SAWP Meeting European Medicines Agency
October 30, 2012 Rome (I) Conferenza Stampa “Farmaci biologici e farmaci biosimilari: tutelare i
pazienti, difendere i brevetti, promuovere l’innovazione, garantire il risparmio. DDL 1875
November 6, 2012 Rome (I) Seconda Conferenza Nazionale sul Diabete
November 12-13, 2012 Cernobbio (I) 3a Conferenza Nazionale sulla Ricerca Sanitaria
November 17, 2012 Bari (I) Welfare e Sanità
November 23, 2012 Rome (I) Informal Meeting COMP and PDCO
November 22-24, 2012 Florence (I) 29° Congresso Nazionale SIMG
November 24-29, 2012 Manaus (BR) 7th Summit of Heads of Medicines Regulatory Agencies
December 5-6,2012 Rome (I) V Conferenza Nazionale sui Dispositivi Medici
December 10, 2012 Rome (I) 109° Conferenza Permanente dei Presidenti di Consiglio di Corso di
Laurea Magistrale in Medicina e Chirurgia
December 11, 2012 Rome (I) Relazione sullo Stato Sanitario del Paese per l’anno 2011
December 13, 2012 London (UK) EMA Management Board
December 19, 2012 Rome (I) Programma Nazionale in materia sanitaria “Le idee per la sanità del
futuro. Un confroto aperto con gli operatori del settore.
January 10, 2013 Catania (I) Dodicesima Conferenza Nazionale sulla farmaceutica
January 14-16,2013 Milan (I) 1st ESTRO Congress
January 28-31, 2013 London (UK) SAWP Meeting European Medicines Agency
February 5, 2013 London (UK) EMA - MBTC meeting
February 8, 2013 Rome (I) Farmaci. Diritto di Parola
February 14-16, 2013 Rome (I) Gender and Science
February 28, 2013 Rome (I) Giornata Mondiale delle Malattie Rare
March, 4-8, 2013 Amsterdam (NL) Dia Euromeeting
March, 8-9 March, 2013 PIetrasanta (I) AMEF 2013 – Expert Forum on Addiction Medicine
March 25, 2013 Rome (I) Meridiano Sanità – Diabete 2020
April 23-24, 2013 Dublin (IRL) Heads of Medicines Agencies Meeting (HMA)
May 3, 2013 Bari (I) Giornata su Farmaco e Prodotti per la Salute
May 6-7, 2013 London (UK) SAWP Meeting European Medicines Agency
May 8, 2013 Bologna (I) 69° Congresso Nazionale della Società Italiana di Pediatria
May 28, 2013 Dublin (IRL) Health Brain Conference (European Commission)
May 29-31, 2013 Chia Laguna (I) 6° Forum Nazionale Pharma
June 3-5, 2013 London (UK) SAWP Meeting European Medicines Agency
June 8, 2013 Rome (I) New trends in cardiovascular drug therapy
June 13, 2013 London(UK) Management Board Meeting of EMA
June 23-25,2013 Boston (USA) DIA Annual Meeting
July 2, 2013 Rome (I) Tavola Rotonda “Riflessioni sui 10 anni passati e (forse) futuri di federalismo
sanitario in Italia” – I-Com Istituto per la competitività
July 3, 2013 Rome (I) L'industria del farmaco: innovazione continua. Ricerca, produzione,
occupazione per la crescita del Paese. Farmindustria
July 8-10, 2013 London (UK) SAWP Meeting European Medicines Agency
July 13, 2013 Cortina (I) 1st Annual MGH CTNI Europe Meeting on CNS Drug Development
July 16, 2013 Rome (I) Appropriatezza clinica strumentale e operativa nella prevenzione, diagnosi e
terapia dei disturbi dell'alimentazione
August 25-28 2013 Seattle (USA)
IDRI Meeting September 3-5, 2013 London (UK)
SAWP Meeting European Medicines Agency September 6, 2013 London (UK) Workshop on Conflict
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 23 / 25
Curriculum Vitae
Luca Pani
of Interest
September 10, 2013 Vilnius (Lithuania) 73rd HMA Meeting, 10th September 2013
September 17-19 2013 Washington (USA) Workshop on "Ensuring the Safety and Quality of the
Global Supply Chain for Medicines: Regulatory Challenges and Lessons from Other Sectors,"
sponsored by the Council on Foreign Relations (CFR)
September 20, 2013 Pula (Cagliari) Incontro con i principali player del distretto Biomed regionale in
Sardegna
September 25-26, 2013 Rome (I) 36° Annual WHO
September 26, 2013 Rome (I) CREA Sanità - Presentazione IX Rapporto Sanità
September-October 30-09/2, 2013
London (UK) SAWP Meeting European Medicines AgencyOctober 3, 2013
London (UK) Management Board Meeting of EMA
October 4, 2013 London (UK) CNS Working Party
October 8, 2013 Rome (I) Premio letterario Leggi in Salute Angelo Zanibelli
October 10, 2013 Padua (I) 3° Congresso Nazionale sulla Medicina di Genere
October 13, 2013 Bergamo (I) BERGAMOSCIENZA XI EDIZIONE
October 14, 2013 Sassari (I) La funzione delle agenzie regolatorie nello sviluppo del farmaco –
Università di Sassari Dipartimento di Scienze Biomediche
October 15, 2013 Rome (I) Presentazione libro Censis: Disponibilità e Certificazione dei dati statistici
in Sanità
October 16, 2013 Rome (I) Convegno “Federalismo in (poca) salute: una ricetta da riscrivere”
October 16, 2013 Rome (I) Festa nazionale del Medico di famiglia
October 16, 2013 Torino (I) XXXIV Congresso Nazionale SIFO
October 23, 2013 Torino (I) 36° Congresso della Società Italiana di Farmacologia (SIF)
October 26, 2013 Rome (I) XLII Congresso Nazionale ANMIRS “Il mercato della speranza. Quando
terapie non efficaci vengono utilizzate lo stesso”
October 31, 2013 Rome (I) “La salute di genere: una proposta per il futuro” ISS
November 4-5,2013 London (UK) SAWP Meeting European Medicines Agency
November 6,2013 London (UK) EU TELEMATICS MANAGEMENT BOARD (EU TMB)
November 9,2013 Bari (I) IX Edizione del CADUCEO d'Oro
November 12,2013 Padova (I) SYMPOSIUM FACING A REVOLUTION IN HCV THERAPY
November 21,2013 Firenze (I) 30° Congresso Nazionale della Società Italiana di Medicina Generale SIMG
November 22, 2013 Pisa (I) Terapie avanzate: armonizzare regole e innovazione per nuove
opportunità di cure FARMINDUSTRIA
November 22,2013 Rome (I) La Malattia Maniaco-Depressiva: l’eredità di Athanasios Koukopoulos.
Azienda Ospedaliera Sant’Andrea
November 23, 2013 Rome (I) FACE-TO-FACE HIV. Fondazione ICONA
November 24-25, 2013 Rome (I) Workshop on Heart Failure. Fondazione Lorenzini
November 26 2013 London (UK) EMA/HTA Parallel Scientific Advice Workshop; CNS Working party
November 26-28, 2013 London (UK) SAWP Meeting European Medicines Agency
November 30, 2013 Rimini (I) II congresso corte di giustizia popolare per il diritto alla salute FEDERANZIANI
December 3, 2013 London (UK) “Adaptive Pathways for Personalised Medicines – Supporting
Innovation in Europe”
December 3, 2013 London (UK) “Adaptive Pathways for Personalised Medicines – Supporting
Innovation in Europe”
December 4-6, 2013 Amsterdam (NL) Summit 2013 Amsterdam 8th International Summit of Heads of
Medicines Regulatory Agencies
December 8, 2013 Naples (I) Melanoma Bridge 2013
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 24 / 25
Curriculum Vitae
Luca Pani
December 11-12, 2013 London (UK) Management Board Meeting of EMA
Other Relevant Information
Mother tongue(s) Italian
Other language(s)
ENGLISH Proficient User
FRENCH Basic User
SPANISH Basic User
Organisational / managerial skills
During the last couple of years Luca Pani has supervised and followed to conclusion several project
and research grants both at regional, national and international level.
All major molecular biology techniques with particular respect to gene expression;
General Pharmacology; Brain Microdyalisis;
Advanced Clinical Skills in Psychiatry
Computer skills
Advanced Knowledge of PC and Mac main Programs;
Founder and Scientific Technical Supervisor of several Website see for example:
www.medol.com (One of the first www site with links to controlled medical information)
www.brainlab.it (A sponsor based site with the largest psychiatric on-line community in Italy)
www.case-builder.com (The first global company that is enterly based on educational interactive
algotithms)
Other skills
Radio Series:
Astolfo Sulla Terra,
Fantasy Fairy Tales Series (with GM De Muro and S Carta)
RAI, Italian National Broadcast Network, 1978-1979
Books:
Pani L.
Le Carte di Ephedra.
Kalb Editore, Cagliari, Italy 2007 (168 pp.)
Tennis Player, Amateur Ranking
Driving licence
Italian Driver Licence type A and B;
Held for several year Driver Licence in California, Illinois and Washington D.C.; Florida (current # DL
PXXXXXXXXX60);
Nautical Licence Sail and Power (unlimited from the coast);
Licence to operate a radiotelegraph on vessels.
19/12/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 25 / 25

Download Report